Activity and Toxicity of Pembrolizumab for NSCLC

July 10, 2014
Naiyer A. Rizvi, MD

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses pembrolizumab (MK-3475) for the treatment of non-small cell lung cancer (NSCLC).

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses pembrolizumab (MK-3475) for the treatment of non-small cell lung cancer (NSCLC).

Activity

- Pembrolizumab has been explored in NSCLC in the first-line and in previously treated patients.

- Good activity has been seen in PD-L1-positive patients.

Toxicity

- Pembrolizumab is generally well tolerated and elicited few significant adverse events.

- Some mild fatigue and pruritus were reported.